目的 觀察布拉酵母菌聯(lián)合舒肝寧注射液治療新生兒高膽紅素血癥的臨床療效。方法 選取2014年6月-2015年6月在湖北醫(yī)藥學(xué)院附屬人民醫(yī)院進(jìn)行治療的新生兒高膽紅素血癥的患兒70例,隨機(jī)分為對(duì)照組和治療組,每組各35例。對(duì)照組患兒靜脈滴注舒肝寧注射液,10 mL加入到10%葡萄糖注射液250 mL,1次/d,癥狀緩解后可改用肌內(nèi)注射2 mL/次,1次/d。治療組患兒在對(duì)照組的基礎(chǔ)上給予布拉氏酵母菌散,1袋/次,1次/d。兩組患兒均治療2周。觀察兩組患兒的臨床療效,同時(shí)比較兩組治療前后膽紅素水平和常見(jiàn)臨床指標(biāo)的變化。結(jié)果 治療后,對(duì)照組和治療組的總有效率分別為80.00%、94.29%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患兒血清膽紅素水平和經(jīng)皮測(cè)定膽紅素水平均顯著下降,同組治療前后差異比較具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療后治療組這些觀察指標(biāo)的下降幅度明顯優(yōu)于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組患兒日均膽紅素下降值明顯大于對(duì)照組,而黃疸消退時(shí)間和藍(lán)光治療時(shí)間明顯短于對(duì)照組,兩組這些觀察指標(biāo)比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 布拉氏酵母菌聯(lián)合舒肝寧注射液治療新生兒高膽紅素血癥具有較好的臨床療效,可顯著降低患兒體內(nèi)膽紅素水平,縮短黃疸消退時(shí)間及藍(lán)光治療時(shí)間,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To understand the distribution and drug resistance analysis of pathogenic bacteria causing lower respiratory tract infection in Second Affiliated Hospital of Tianjin University of TCM, and to provide reference for clinical rational drug use. Methods The distribution and drug resistance analysis of pathogenic bacteria causing lower respiratory tract infection in Second Affiliated Hospital of Tianjin University of TCM in 2015 were analyzed retrospectively. Results Total 662 strains of pathogens were isolated, in which Gram-negative bacteria were 504 strains (76.13%). Gram-positive bacteria (60 strains) accounted for 9.06%. While there were also 98 strains of fungus (14.80%) isolated. The sensitive rate of main Gram-negative bacteria against meropenem was above 82%. Different bacteria had different sensitive rates against the same antibacterial drug. And Gram-negative bacteria and Gram-negative bacteria generally had the phenomenon of multiple drug resistance. The sensitive rates of Candida albicans against amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, and voriconazole were above 98%. Conclusion The main pathogens causing lower respiratory tract infection is Gram-negative bacteria. The different drug resistance exists in different kinds of bacteria. The physician should understand local pathogenic bacteria distribution and drug resistance timely, in order to guide the clinical empirical use of antibacterial drugs.